Prebiotics Constipation Meta-analysis: What the Evidence Says

Quick Answer

Prebiotics Constipation Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 narrative review, 1 preclinical study.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Irritable bowel syndrome (IBS) is a chronic disorder of gut-brain interaction characterized by recurrent abdominal pain associated with altered bowel habits, in the absence of identifiable structural abnormalities. [Šuran Jelena (2026); evidence level 3]
• Early studies reported SIBO in up to 60-78% of IBS cases based on lactulose breath testing, though later investigations using more rigorous methods found lower prevalences (e.g., 4-20%). [Šuran Jelena (2026); evidence level 3]
• Gut microbiota dysbiosis is recognized as a common key link: patients with both constipation and depression often exhibit reduced microbial diversity, decreased short-chain fatty acids (SCFAs), lower abundance of probiotic genera (e.g., Bifidobacterium,), and heightened inflammation (;;;;;;;). [Dai Qiuhua (2026); evidence level 4]
• Despite generally high safety profiles, existing clinical evidence remains controversial due to significant heterogeneity and uncertain efficacy, and the underlying mechanisms remain unclear (;;;). [Dai Qiuhua (2026); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

For prebiotics constipation meta-analysis, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Šuran Jelena (2026). IBS and SIBO: Gut Microbiota, Pathophysiology, and Non-Pharmacological Interventions. DOI: 10.3390/antibiotics15030251. PMCID: PMC13023761. PMID: 41892413. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13023761/
• Dai Qiuhua (2026). Research progress and controversies in the treatment of functional constipation-related depression with probiotics and prebiotics: a narrative review. DOI: 10.3389/fphar.2026.1735614. PMCID: PMC12946840. PMID: 41769687. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12946840/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.